PL3497095T3 - Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego - Google Patents

Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego

Info

Publication number
PL3497095T3
PL3497095T3 PL17757819T PL17757819T PL3497095T3 PL 3497095 T3 PL3497095 T3 PL 3497095T3 PL 17757819 T PL17757819 T PL 17757819T PL 17757819 T PL17757819 T PL 17757819T PL 3497095 T3 PL3497095 T3 PL 3497095T3
Authority
PL
Poland
Prior art keywords
treatment
bacterial infection
chelating compounds
zinc chelating
zinc
Prior art date
Application number
PL17757819T
Other languages
English (en)
Inventor
Pål RONGVED
Ove Alexander Høgmoen ÅSTRAND
Ørjan SAMUELSEN
Christian SCHNAARS
Geir KILDAHL-ANDERSEN
Original Assignee
Universitetet I Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet I Oslo filed Critical Universitetet I Oslo
Publication of PL3497095T3 publication Critical patent/PL3497095T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
PL17757819T 2016-08-15 2017-08-15 Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego PL3497095T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1613946.1A GB201613946D0 (en) 2016-08-15 2016-08-15 Compounds
PCT/GB2017/052401 WO2018033719A1 (en) 2016-08-15 2017-08-15 Compounds
EP17757819.2A EP3497095B1 (en) 2016-08-15 2017-08-15 Zinc chelating compounds for use in the treatment of bacterial infection

Publications (1)

Publication Number Publication Date
PL3497095T3 true PL3497095T3 (pl) 2021-12-20

Family

ID=56985884

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17757819T PL3497095T3 (pl) 2016-08-15 2017-08-15 Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego

Country Status (8)

Country Link
US (2) US10961223B2 (pl)
EP (2) EP3497095B1 (pl)
CN (1) CN109952297B (pl)
DK (1) DK3497095T3 (pl)
ES (1) ES2893803T3 (pl)
GB (1) GB201613946D0 (pl)
PL (1) PL3497095T3 (pl)
WO (1) WO2018033719A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020148325A1 (en) 2019-01-15 2020-07-23 Phenex-Fxr Gmbh Neutral lxr modulators
WO2020236084A1 (en) * 2019-05-17 2020-11-26 Singapore Health Services Pte Ltd Molecular design of new antibiotics and antibiotic adjuvants against mcr strains
CN111718361B (zh) * 2020-07-23 2022-04-05 南京工业大学 一种金属β-内酰胺酶抑制剂及其制备方法与应用
WO2023164114A2 (en) * 2022-02-24 2023-08-31 The Research Institute At Nationwide Children's Hospital Bacterial biofilm inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010225A1 (en) 1995-09-15 1997-03-20 Smithkline Beecham Plc Pyrrolidine and thiazole derivatives with antibacterial and metallo-beta-lactamase inhibitory properties
US6127393A (en) 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
JP2000506120A (ja) 1996-02-13 2000-05-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ベータ―チオプロピオニル―アミノ酸およびそのベータ―ラクタマーゼ阻害剤としての使用
AU5050198A (en) 1996-10-17 1998-05-15 Smithkline Beecham Plc Beta-thiopropionyl-amino acid derivatives and their use as beta-lactamase inhibitors
GB9704522D0 (en) 1997-03-05 1997-04-23 Smithkline Beecham Plc Compounds
WO1998040056A2 (en) 1997-03-13 1998-09-17 Smithkline Beecham Plc Pyrrolidine and thiazole derivatives with metallo-beta-lactamase inhibitory properties
US20070154948A1 (en) 1999-05-24 2007-07-05 Christensen Burton G Novel antibacterial agents
EP1192128A4 (en) 1999-06-15 2003-07-02 Merck & Co Inc THIOL DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS
EP1227722A1 (en) 1999-10-28 2002-08-07 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
US6630510B1 (en) 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
US7527807B2 (en) 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
US6803379B2 (en) 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2003280590A1 (en) 2002-10-29 2004-05-25 Hanaki, Hideaki Mr Beta -lactamase detecting reagent composition, detection kit and detection method
US8404852B2 (en) * 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
WO2004071425A2 (en) 2003-02-06 2004-08-26 Bioresponse, Llc The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
EP1644024B1 (en) 2003-06-06 2019-07-31 Board of Regents, The University of Texas System Antimicrobial flush solutions
JP3977411B2 (ja) 2004-03-10 2007-09-19 株式会社クレハ アミン系塩基性化合物とその用途
WO2005117997A1 (en) 2004-06-01 2005-12-15 The Ohio State University Ligands having metal binding ability and targeting properties
WO2006043153A2 (en) 2004-10-20 2006-04-27 Michel Xilinas Use of zinc and copper chelators for the treatment of viral diseases
GB0507490D0 (en) 2005-04-14 2005-05-18 Aq & Plc Treatment of animal parasites
WO2006117660A2 (en) 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
GB0717182D0 (en) 2007-09-04 2007-10-17 Danisco Composition
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
AU2009260414A1 (en) 2008-05-30 2009-12-23 University Of Cincinnati Use of zinc chelators to inhibit biofilm formation
WO2010036814A1 (en) * 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
JP2013511555A (ja) 2009-11-23 2013-04-04 スティーブン エフ オルムステッド 特定の症状に関連するバイオフィルムの抑制及び治療のための、セラチア・ペプチダーゼを含む組成物及び方法
US20120329842A1 (en) 2010-12-23 2012-12-27 Yongcheng Song Small molecule compounds as broad-spectrum inhibitors of metallo-beta-lactamases
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
WO2014089365A1 (en) * 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
KR20170024087A (ko) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
EP3172222A4 (en) 2014-07-24 2018-03-21 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
CN105669750B (zh) * 2016-03-01 2018-04-03 中国医学科学院医药生物技术研究所 新型锌离子螯合剂及其制备和在抗革兰氏阴性菌感染中的应用

Also Published As

Publication number Publication date
EP3978488A1 (en) 2022-04-06
US11649222B2 (en) 2023-05-16
EP3497095B1 (en) 2021-07-14
CN109952297B (zh) 2022-02-25
ES2893803T3 (es) 2022-02-10
CN109952297A (zh) 2019-06-28
GB201613946D0 (en) 2016-09-28
US20190284167A1 (en) 2019-09-19
WO2018033719A1 (en) 2018-02-22
US20210221791A1 (en) 2021-07-22
EP3497095A1 (en) 2019-06-19
US10961223B2 (en) 2021-03-30
DK3497095T3 (da) 2021-10-04

Similar Documents

Publication Publication Date Title
HRP20190580T1 (hr) Kombinirana terapija radi liječenja rezistentnih bakterijskih infekcija
HK1249033A1 (zh) 用於治療細菌感染的殺菌劑與親溶酶體鹼化劑的組合
IL271863B (en) Compounds and their use for the treatment of microbial infections
EP3468555C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
GB201813876D0 (en) Treatment
PL3497095T3 (pl) Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego
HK1243951A1 (zh) 抗微生物組合和其在治療微生物感染中的用途
GB201800546D0 (en) Treatment
LT3405213T (lt) Bakteriniai šešėliai, skirti panaudoti vėžio gydyme
GB201617820D0 (en) Dental treatment
PT3285787T (pt) Tratamento de infeções bacterianas em aquicultura
IL281770A (en) History of indan for the treatment of bacterial infection
PL3548052T3 (pl) Zastosowanie mieszanki bakteryjnej do leczenia zakażeń stopy u zwierząt kopytnych
IL252493B (en) Compounds for use in the prevention or treatment of cancer
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL253418A0 (en) Nisin-based compounds and their use in the treatment of bacterial infections
GB2558090B (en) Prevention and treatment for microbial infections
SG10201405850PA (en) Composition for prevention or treatment of urinary tract infection
SG11202100269VA (en) Compounds for use in the treatment of fascioliasis
GB201814905D0 (en) Treatment
GB201708650D0 (en) Combination therapy for bacterial infection
GB201702703D0 (en) Waste Treatment
GB201604773D0 (en) Waste treatment
AU2015903720A0 (en) Body treatment composition
AU2014901912A0 (en) Compounds for the treatment of bacterial infections